Impact of PROphet Test in Changing Physicians' Therapeutic Decision-Making for Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer.
David R GandaraJanakiraman SubramanianEdgardo S SantosYehuda BrodyItamar SelaYehonatan ElonMichal HarelAnat Reiner-BenaimCoren LahavKimberly McGregorPublished in: Clinical lung cancer (2024)
Adding PROphet to PD-L1 expression impacted therapeutic decision making in first-line NSCLC. PROphet identifies those predicted to have an overall survival benefit from ICI monotherapy versus combination versus chemotherapy, improving the probability of efficacy and reducing toxicity for some patients.
Keyphrases
- end stage renal disease
- decision making
- small cell lung cancer
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- oxidative stress
- squamous cell carcinoma
- clinical trial
- randomized controlled trial
- open label
- combination therapy
- patient reported outcomes
- radiation therapy
- study protocol
- patient reported